Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase

Tumor Biology

Volumn 30, Issue 2, 2009, Pages 80-85

  Yu, Sandy Yee Man ^a   Chan, David Wai ^a   Liu, Vincent Wing Sun ^a   Ngan, Hextan Yuen Sheung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

AICAR; AMP activated protein kinase; CaMKK; Cervical cancer; LKB1

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CALCIMYCIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE LKB1; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; CAMKK2 PROTEIN, HUMAN; DRUG DERIVATIVE; ENZYME ACTIVATOR; GROWTH INHIBITOR; PROTEIN SERINE THREONINE KINASE; RIBONUCLEOTIDE; STK11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; CALCIMYCIN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; GROWTH INHIBITORS; HELA CELLS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 65449173255     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000216843     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74 -108 .
2. Nishio S, Katsumata N, Matsumoto K, Ta-nabe H, Yonemori K, Kohno T, Shimizu C, Ando M, Kasamatsu T, Fujiwara Y: Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. Oncol Rep 2008; 19: 497-503.
3. Robinson-Bennett BL, Deford J, Diaz-Arrastia C, Levine L, Wang HQ, Hannigan EV, Pa-paconstantinou J: Implications of tyrosine phosphoproteomics in cervical carcinogen-esis. J Carcinogen 2008; 7:2.
4. Luo Z, Saha AK, Xiang X, Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005; 26:69-76.
5. Hardie DG: New roles for the LKB1→AMPK pathway. Curr Opin Cell Biol 2005; 17: 167-173.
6. Carling D: The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 2004; 29:18-24.
7. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007; 6: 46.
8. Motoshima H, Goldstein BJ, Igata M, Araki E: AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71.
9. Hadad SM, Fleming S, Thompson AM: Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67: 1-7.
10. Huang X, Wullschleger S, Shpiro N, Mc-Guire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412:211-221.
11. Garcia-Gil M, Pesi R, Perna S, Allegrini S, Giannecchini M, Camici M, Tozzi MG: 5′-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells. Neuroscience 2003; 117:811-820.
12. Campas C, Lopez JM, Santidrian AF, Barra-gan M, Bellosillo B, Colomer D, Gil J: Acade-sine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003; 101: 3674-3680.
13. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Bio-phys Res Commun 2004; 321:161-167.
14. Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ: The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 2007; 282:10341-10351.
15. Corton JM, Gillespie JG, Hardie DG: Role of the AMP-activated protein kinase in the cellular stress response. Curr Biol 1994; 4:315-324.
16. Ji H, Ramsey MR, Hayes DN, Fan C, McNa-mara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Linde-man NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiat-kowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK: LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
17. Sanchez-Cespedes M: A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007; 26: 7825-7832.
18. Huang FY, Kwok YK, Lau ET, Tang MH, Ng TY, Ngan HY: Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet 2005; 157: 42-48.
19. 2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2: 21-33.
20. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG: Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005; 2: 9-19.
21. Carling D: AMP-activated protein kinase: balancing the scales. Biochimie 2005; 87:87-91.
22. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG: Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
23. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley, LC: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101: 3329-3335.
24. Tiainen M, Ylikorkala A, Makela TP: Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA 1999; 96:9248-9251.
25. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002; 277:23977-23980.
26. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
27. Scott JW, Ross FA, Liu JK, Hardie DG: Regulation of AMP-activated protein kinase by a pseudosubstrate sequence on the gamma subunit. EMBO J 2007; 26:806-815.
28. Viana AY, Sakoda H, Anai M, Fujishiro M, Ono H, Kushiyama A, Fukushima Y, Sato Y, Oshida Y, Uchijima Y, Kurihara H, Asano T: Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract 2006; 73: 135-142.
29. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M, Esumi H: Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21:6082-6090.
30. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Naka-maru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa T, Araki E: Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005; 97:837-844.
31. Rattan R, Giri S, Singh AK, Singh I: 5-Ami-noimidazole-4-carboxamide-1- β-D-ribofu-ranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005; 280:39582-39593.
32. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B: 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor mi-croenvironments. Mol Cell Biol 2006; 26: 5336-5347.
33. Imamura K, Ogura T, Kishimoto A, Kamin-ishi M, Esumi H: Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001; 287: 562-567.
34. Mehenni H, Gehrig C, Nezu J, Oku A, Shi-mane M, Rossier C, Guex N, Blouin JL, Scott HS, Antonarakis SE: Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998; 63:1641-1650.
35. Ylikorkala A, Avizienyte E, Tomlinson IP, Tiainen M, Roth S, Loukola A, Hemminki A, Johansson M, Sistonen P, Markie D, Neale K, Phillips R, Zauber P, Twama T, Sampson J, Jarvinen H, Makela TP, Aaltonen LA: Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet 1999; 8:45-51.
36. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-590.
37. 2+ /calmod-ulin-dependent protein kinase kinase α as Snf1-activating kinases in yeast. J Biol Chem 2005; 280: 21804-21809.
38. Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA: Phosphatidylinositol ether lipid analogues induce AMP-activated protein ki-nase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res 2008; 68:580-588.